A team of US researchers are conducting studies to understand whether botanical therapies like medicinal mushrooms and Chinese herbs provide therapeutic benefit in treating acute Covid-19 cases.
According to principal investigator Gordon Saxe, director of research at the Center for Integrative Health in University of California-San Diego, mushrooms were chosen because of their long history of use and recent evidence of immune-enhancing and antiviral effects.
MACH-19 (Mushrooms and Chinese Herbs for Covid-19) is a multi-centre study led by UC San Diego's School of Medicine and UC-Los Angeles, in collaboration with the La Jolla Institute for Immunology.
In a preclinical study published in 2019, mushroom agarikon was found to inhibit viruses, including influenza (H1N1), influenza A (H5N1) and herpes. Saxe said he believes medicinal mushrooms inhibit the viruses' replication, a theory he plans to test against SARS-CoV-2 in a Phase II trial.
"Mushrooms have the advantage that they co-evolved with us. So bacteria, viruses and other fungi prey on mushrooms just like they prey on humans. And mushrooms have developed exquisite defenses against those pests, and we believe they can confer those to us when we eat them," Saxe said.
MACH-19's third ongoing trial measures whether the same medicinal mushrooms, given in capsules at the time of initial Covid vaccination, can increase antibodies and other measures of immune response.
A fourth trial, yet to be launched, will look at whether medicinal mushrooms could provide a similar lift to Covid-19 booster shots as an adjuvant, a substance which enhances immune response.
"Vaccines lead to the production of antibodies that can destroy the virus in the blood," Saxe said.
"Mushrooms may not only increase the number of these antibodies, but also enhance T-cell immunity against virally infected cells. Further, because mushrooms bind to receptors on human immune cells, they can modulate our immunity -- boosting it in some ways and calming it down in others. And this property of mushrooms may also reduce vaccine-related side effects.
Natural therapeutics have been used for centuries to treat infectious diseases, according to Saxe, who noted that herbs helped Chinese doctors manage 300 recorded epidemics, while the Greek pharmacologist Pedanius Dioscorides prescribed agarikon to treat pulmonary infections 2,300 years ago.
The three trials, under MACH-19 of which two are Food and Drug Administration (FDA)-approved, are currently recruiting for between 66 and 80 patients who have tested positive for SARS-CoV-2 and who are quarantined at home with mild to moderate symptoms.AInitial safety data from the trials are expected by the end of this year, with efficacy data ready within a year.
Read More► Psychiatric Disorders in Teens Linked to Social Exclusion in Later Life
New York, May 4 (IANS) A team of researchers has designed a 3D "lung-on-a-chip" model that replicates human alveolar lung tissue to test new therapies for Covid-19 and other lung conditions.The model will help study how Covid viral particles travel through airways and impact pulmonary cells. The technology also enables scientists to investigate how various Covid therapies, such as Remdesivir, impact the replication of the virus."This is a first-of-its-kind in vitro model of the human lower lung that can be used to test many of the biological mechanisms and therapeutic agents, including antiviral drugs for Covid-19 research," said Y Shrike Zhang, Associate Bioengineer, Department of Medicine and Division of Engineering in Medicine at Brigham and Women's Hospital in the US.The team developed this technology to mirror the biological characteristics of the human distal lung. They found that the 3D alveolar lung effectively grew cells over multiple days and that these cells adequately populated airway surfaces. Through genome sequencing, scientists observed that the alveolar lung model more closely resembled the human distal lung than previous 2D models have.AAdditionally, the lung-on-a-chip model successfully stimulated breaths of air at the normal frequency for humans.The team intends to use this technology to study a broad range of pulmonary conditions, including various lung cancers. To replicate smoking's impact on the lungs, scientists allowed smoke to seep into the model's air chambers then simulated a breathing event, moving smoke deeper into the lungs. From there, they measured the smoke's impact and cell damage it caused.While this innovation holds the potential to vastly expand the possibilities of studying and treating pulmonary diseases, this model is still in its early stages, said Zhang.Currently, the alveolar lung-on-a-chip only incorporates two out of the 42 cell types existing in the lung. In the future, researchers hope to incorporate more cell types into the model to make it more clinically representative of human lungs, Zhang noted.--IANSrvt/in
Ministry of AYUSH has formed an Inter-disciplinary AYUSH R&D Task Force chaired by Prof. Bhushan Patwardhan and having representation from scientists including Indian Council of Medical Research (ICMR), Department of Biotechnology(DBT), Council of Scientific and Industrial Research (CSIR), All India Institute of Medical Sciences (AIIMS) and AYUSH Institutions.
The Interdisciplinary AYUSH Research and Development Task Force has formulated and designed clinical research protocols for prophylactic studies and add-on interventions in COVID-19 positive cases through thorough review and consultative process of experts of high repute from different organizations across the country for studying four different interventions viz.
Ashwagandha, Yashtimadhu, Guduchi + Pippali and a poly herbal formulation (AYUSH-64).The task force have taken up the proposals received from screening committees of Councils and proactively explored possibilities based on available leads.
Ministry of AYUSH has constituted core group of experts under the Chairmanship of Prof. Bhushan Patwardhan to identify and propose formulations on COVID-19 which are in line with Classical Ayurveda principles and have substantial leads on COVID-19 viz. one for prophylaxis as immunomodulatory, another for management of COVID-19 with antiviral properties and one product for post COVID-19 care.
Ministry of AYUSH has launched interdisciplinary studies involving AYUSH interventions for COVID-19 based on recommendations of Task force. Under various research organizations and National Institutes under Ministry of AYUSH, 112 research studies at 141 centres in the country are being conducted on AYUSH interventions as prophylactic interventions.
AYUSH Sanjivani mobile app developed by Ministry of AYUSH and has documented the impact assessment of effectiveness, acceptance and usage of AYUSH advisories & measures in the prevention of COVID-19 through Mobile app base population study in around 1.5 crores respondents. 85.1% of the respondents reported use of AYUSH measures for prevention of COVID-19, among which 89.8% respondents agreed to have benefitted from the practice of AYUSH advisory.
The Ministry of AYUSH has released “National Clinical Management Protocol based on Ayurveda and Yoga for management of COVID-19” prepared by National Task force which in consensus from expert committees from All India Institute of Ayurveda (AIIA), Delhi, Institute of Post Graduate Training and Research in Ayurved (IPGTRA), Jamnagar, and National Institute of Ayurveda (NIA), Jaipur , Central Council for Research in Ayurveda (CCRAS), Central Council for Research in Yoga and Naturopathy (CCRYN) and other national research organizations as per the Report & Recommendations of the Interdisciplinary Committee.
The Minister of State (The Ministry of Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homeopathy), Sh. Kiren Rijiju (Additional Charge) stated this in a written reply in the Rajya Sabha here today.
Read More► Promotion of Ayurvedic Medicines in the country
In Ayurveda insomnia is acknowledged by the name of ‘anidra’. It implies that insomnia can be relieved by balancing intensified body energies. The route it follows? By following suitable lifestyle choices, a customized diet, and taking medicines recommended by an Ayurvedic doctor. Besides that, relaxation of the mind is also a crucial part of the treatment. Here are 7 home remedies for Insomnia.
1.Reduce Screen Time
Shut all screens two hours before you go to bed. The blue light emanating from screens affects the production of the sleep-inducing hormone melatonin.
2.Relax with Yoga and Meditation
Yoga, breathing exercises, and meditation are excellent ways to relax the mind and allow it to sleep. Know how meditation can help deal with insomnia.
3.Have This Concoction
Boil 3 grams of fresh mint leaves or 1.5 grams of dried powder of mint leaves in 1 cup of water for 15-20 minutes. Take lukewarm with 1 teaspoon of honey at bedtime.
4.Sip Warm Milk Before Bed
Milk stimulates the production of melatonin, the sleep-inducing hormone.
5.Tap the Power of Ayurvedic Therapies
Ayurvedic therapies like Shirodhara help relax the mind and quell disorders like insomnia. Consult an Ayurvedic doctor to know which therapies are best suited for your system.
6.Sport or Workout
Practice a sport or workout for at least 30 minutes daily to tire your body and channelize the energy. Know how yoga can help you deal with insomnia.
If you are suffering from extreme insomnia, stop consumption of all caffeine drinks, coffee, tea, and aerated drinks. If you are suffering from mild insomnia, then do not drink them after dusk.
New Delhi, Sep 23 (IANS) The Council of Scientific and Industrial Research (CSIR), India's premier research organisation, and Mylan Laboratories Ltd on Wednesday announced a partnership to address unmet patient needs amidst the evolving Covid-19 pandemic.Under the partnership, CSIR's constituent laboratory, the Indian Institute of Chemical Technology (CSIR-IICT), and Mylan will collaborate to identify potential therapies for Covid-19.A series of clinical trials will be conducted towards new and innovative solutions to manage the Covid-19 pandemic in India as part of this collaboration. The first of the clinical trials to be rolled out is a multiple arm Phase-3 study that will be conducted in adult patients with mild to moderate Covid-19 at risk of complications.CSIR Director General, Dr. Shehkar C Mande said: "The current collaboration with Mylan is a significant milestone and during the current Covid-19 pandemic, CSIR has prioritised conducting clinical trials of well-proven drugs in partnership with industry towards the development of multiple therapeutic options for Covid-19."CSIR-IICT Director, Dr Chandrasekhar said: "CSIR is delighted to associate with Mylan as knowledge and scientific partner, and looks forward to working with the company, especially given Mylan's vast industry experience in clinical trials and commercialisation."Mylan Chief Operating Officer, Sanjeev Sethi said that the collaboration with the CSIR is a strategic step forward aimed at identifying effective treatments for patients with Covid-19. "In addition to bringing forward new indications, this partnership will also help us identify multiple molecules that can potentially be leveraged in therapies for various other infectious diseases in the future."The application for the clinical trials has been submitted to the Drugs Controller General of India (DCGI) for regulatory approval. CSIR has appointed Dr. Ram Vishwakarma, Honorary Advisor to the DG-CSIR and former Director CSIR-IIIM (Indian Institute of Integrative Medicine) as a mentor to lead this collaboration.--IANSaka/vd
Washington, July 9 (IANS) The US National Institute of Allergy and Infectious Diseases (NIAID) announced the establishment of a new clinical trials network aiming to step up vaccines and monoclonal antibodies testing, as the country's COVID-19 cases has surpassed 3 million.The US currently accounts for the world's highest number of infections and fatalities at 3,053,328 and 132,277, respectively, according to the Johns Hopkins University.The new network, called the COVID-19 Prevention Trials Network, will enroll thousands of volunteers in large-scale clinical trials testing a variety of investigational vaccines and monoclonal antibodies intended to protect people from COVID-19, Xinhua news agency reported."Starting this summer, this new network will leverage existing infrastructure and engage communities to secure the thousands of volunteers needed for late-stage clinical trials of promising vaccines," Secretary of Health and Human Services Alex Azar said on Wednesday."Having a safe and effective medical countermeasure to prevent COVID-19 would enable us to not only save lives but also help end the global pandemic," said NIAID Director Anthony Fauci.The new network is expected to operate more than 100 clinical trial sites across the US and internationally, according to the NIAID.It is part of ongoing efforts across the country in speeding up the development of vaccines and therapies against COVID-19.According to Fauci, the US government will fund and conduct key studies on three experimental coronavirus vaccines in the summer.Phase 3 trials, which typically involve tens of thousands of people and measure whether a vaccine is safe and effective, will begin with one by Moderna in July, then an Oxford/AstraZeneca vaccine in August and one by Johnson & Johnson in September.Fauci said that the testing plans still track with the timeline that he has suggested in the past: a vaccine at scale by the end of the year or early next year.Remdesivir, the only drug that has an emergency use authorization from the US Food and Drug Administration to treat COVID-19, has shown promising results and sets a new standard of care for COVID-19 patients.In order to expand the potential uses of the drug against the virus, American biopharmaceutical company Gilead Sciences has announced plans to explore administration of remdesivir in an inhaled form.According to Azar, more than 120,000 courses of remdesivir have been distributed to all of 50 states.Meanwhile, investigators continue to study whether blood-plasma transfusions from recovered COVID-19 patients are safe and improve outcomes for severely-ill patients.More than 28,000 patients have received the transfusions so far, according to a national online registry the Mayo Clinic coordinates. --IANSksk/